ERBB2 and neoplasm: While this upregulation of ER and ER‐related genes leads to a compensatory ‘escape’ pathway, it simultaneously creates an additional therapeutic target, with evidence that sustained anti‐HER2 therapy sensitizes tumor cells to endocrine therapies [7].